For Research Use Only

## P27; KIP1 Polyclonal antibody

Catalog Number:25614-1-AP

Featured Product

216 Publications



asic Information	Catalog Number: 25614-1-AP	GenBank Accession Number: BC001971 GeneID (NCBI): 1027 UNIPROT ID: P46527 Full Name: cyclin-dependent kinase inhibitor 1B (p27, Kip1)		Purification Method: Antigen affinity purification Recommended Dilutions: WB 1:1000-1:8000 IP 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate IHC 1:50-1:500 IF-P 1:200-1:800 IB IF/ICC 1:50-1:500			
	Size: 150ul , Concentration: 700 ug/ml by Nanodrop; Source: Rabbit						
					lsotype: IgG		
					Immunogen Catalog Number: AG22582	Calculated MW: 198 aa, 22 kDa	
					Observed MW: 27 kDa		
	Applications	WB IHC IF/ICC IE-D EC (Intra) ID EUSA		Observed MW: 27 kDa Positive Controls:			
		Cited Applications:	WD: HeLd Cell				
WB, IHC, IF, IP, CoIP			IP:NIH/3T3 ce	ells,			
Species Specificity: human, mouse				preast cancer tissue, human lung cancer			
Cited Species:		tissue, humar tissue		colon cancer tissue, human ovary tumo			
	human, mouse, rat, canine, bovine, s	пеер	IF-P : mouse te	actis tissue			
	Note-IHC: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0		IF/ICC : HepG2 cells,				
	buffer pH 6.0						
Background Information	buffer pH 6.0 CDKN1B, also named as P27 or KIP1, CDK inhibitor CDKN1A/p21. P27 bind and thus controlling cell cycle progre dependent phosphorylation and subs from quiescence to the proliferative malignancies, including lung cancer, gastric cancer.	ls to and prevents the a ssion at G1. The degra sequent ubiquitination state. Downregulation	ctivation of cycl dation of this pro by SCF complex of P27 has been	in E-CDK2 or cyclin D-CDK4 comple- tein, which is triggered by its CDK es, is required for the cellular trans- implicated in the progression of se			
	CDKN1B, also named as P27 or KIP1, CDK inhibitor CDKN1A/p21. P27 bind and thus controlling cell cycle progre dependent phosphorylation and subs from quiescence to the proliferative malignancies, including lung cancer, gastric cancer.	Is to and prevents the a ssion at G1. The degra equent ubiquitination state. Downregulation hepatocellular carcing	ictivation of cycl dation of this pro by SCF complex of P27 has been oma, salivary car	in E-CDK2 or cyclin D-CDK4 comple- otein, which is triggered by its CDK es, is required for the cellular trans- implicated in the progression of se- ncer, oral squamous cell carcinoma			
	CDKN1B, also named as P27 or KIP1, CDK inhibitor CDKN1A/p21. P27 bind and thus controlling cell cycle progre dependent phosphorylation and subs from quiescence to the proliferative malignancies, including lung cancer, gastric cancer.	Is to and prevents the a sission at G1. The degra equent ubiquitination state. Downregulation hepatocellular carcine med ID Journ	activation of cycl dation of this pro- by SCF complex of P27 has been oma, salivary car	in E-CDK2 or cyclin D-CDK4 comple- tein, which is triggered by its CDK es, is required for the cellular trans- implicated in the progression of se- ncer, oral squamous cell carcinoma Application			
Background Information	CDKN1B, also named as P27 or KIP1, CDK inhibitor CDKN1A/p21. P27 bind and thus controlling cell cycle progre dependent phosphorylation and subs from quiescence to the proliferative malignancies, including lung cancer, gastric cancer. Author Pub Yong-Li Zhang 346	Is to and prevents the a sission at G1. The degra equent ubiquitination state. Downregulation hepatocellular carcino med ID Journ 79694 Antio	ictivation of cycl dation of this pro- by SCF complex of P27 has been oma, salivary car al al	in E-CDK2 or cyclin D-CDK4 complete otein, which is triggered by its CDK es, is required for the cellular trans- implicated in the progression of se ncer, oral squamous cell carcinoma Application WB			
	CDKN1B, also named as P27 or KIP1, CDK inhibitor CDKN1A/p21. P27 bind and thus controlling cell cycle progred dependent phosphorylation and subs from quiescence to the proliferative malignancies, including lung cancer, gastric cancer. Author Pub Yong-Li Zhang 346 Qian Chen 329	Is to and prevents the a sistion at G1. The degra equent ubiquitination state. Downregulation hepatocellular carcine med ID Journ 79694 Antio 97272 J Nat	activation of cycl dation of this pro- by SCF complex of P27 has been oma, salivary car al xidants (Basel) Med	in E-CDK2 or cyclin D-CDK4 complete the train, which is triggered by its CDK es, is required for the cellular trans- implicated in the progression of se the transformed set of the transformed transformed set of the transformed Application WB WB			
	CDKN1B, also named as P27 or KIP1, CDK inhibitor CDKN1A/p21. P27 bind and thus controlling cell cycle progred dependent phosphorylation and subs from quiescence to the proliferative malignancies, including lung cancer, gastric cancer. Author Pub Yong-Li Zhang 346 Qian Chen 329	Is to and prevents the a sistion at G1. The degra equent ubiquitination state. Downregulation hepatocellular carcine med ID Journ 79694 Antio 97272 J Nat	ictivation of cycl dation of this pro- by SCF complex of P27 has been oma, salivary car al al	in E-CDK2 or cyclin D-CDK4 complete the train, which is triggered by its CDK es, is required for the cellular trans- implicated in the progression of se the transformed set of the transformed transformed set of the transformed Application WB WB			
	CDKN1B, also named as P27 or KIP1, CDK inhibitor CDKN1A/p21. P27 bind and thus controlling cell cycle progred dependent phosphorylation and subs from quiescence to the proliferative malignancies, including lung cancer, gastric cancer. Author Pub Yong-Li Zhang 346 Qian Chen 329	Is to and prevents the a sission at G1. The degra equent ubiquitination state. Downregulation hepatocellular carcine med ID Journ 79694 Antio 97272 J Nat 06599 Bioch ter shipment.	activation of cycl dation of this pro- by SCF complex of P27 has been oma, salivary car al xidants (Basel) Med	in E-CDK2 or cyclin D-CDK4 complete the train, which is triggered by its CDK es, is required for the cellular trans- implicated in the progression of se the transformed set of the transformed transformed set of the transformed Application WB WB			


T: 1 (888) 4PTGLAB (1-888-478-4522) (toll free E: proteintech@ptglab.com

in USA), or 1(312) 455-8498 (outside USA)


W: ptglab.com

Group brand and is not available to purchase from any other manufacturer.


## Selected Validation Data




Various lysates were subjected to SDS PAGE followed by western blot with 25614-1-AP (P27; KIP1 antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours.




Various lysates were subjected to SDS PAGE followed by western blot with 25614-1-AP (P27; KIP1 antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours.




WB result of P27; KIP1 antibody (25614-1-AP; 1:2000; incubated at room temperature for 1.5 hours) with sh-Control and sh-P27; KIP1 transfected Hela cells.




Immunohistochemical analysis of paraffinembedded human breast cancer tissue slide using 25614-1-AP (P27; KIP1 Antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).




Immunohistochemical analysis of paraffinembedded human breast cancer tissue slide using 25614-1-AP (P27; KIP1 Antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).




IP result of anti-P27; KIP1 (IP:25614-1-AP, 4ug; Detection:25614-1-AP 1:1000) with NIH/3T3 cells lysate 3440 ug.




Immunofluorescent analysis of (4% PFA) fixed mouse testis tissue using P27; KIP1 antibody (25614-1-AP) at dilution of 1:400 and CoraLite@488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).



Immunofluorescent analysis of (4% PFA) fixed mouse testis tissue using P27; KIP1 antibody (25614-1-AP) at dilution of 1:400 and Coralite@488-Conjugated AffiniPure Goat Anti-Rabbit IgC(H+L).



1X10^6 MCF-7 cells were intracellularly stained with 0.4 ug Anti-Human P27; KIP1 (25614-1-AP) and Coralite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) at dilution 1:1000 (red), or 0.4 ug Control Antibody. Cells were fixed and permeabilized with Transcription Factor Staining Buffer Kit (PF00011).



Immunofluorescent analysis of (4% PFA) fixed HepG2 cells using P27; KIP1 antibody (25614-1-AP) at dilution of 1:200 and CoraLite®594-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-4), CL488-Phalloidin (green).